BR9714312A - Método de tratamento de bronquite com trifosfato de uridina e composto relacionados - Google Patents

Método de tratamento de bronquite com trifosfato de uridina e composto relacionados

Info

Publication number
BR9714312A
BR9714312A BR9714312-0A BR9714312A BR9714312A BR 9714312 A BR9714312 A BR 9714312A BR 9714312 A BR9714312 A BR 9714312A BR 9714312 A BR9714312 A BR 9714312A
Authority
BR
Brazil
Prior art keywords
uridine
bronchi
clearance
bronchioles
utp
Prior art date
Application number
BR9714312-0A
Other languages
English (en)
Inventor
Christy L Shaffer
Richard C Boucher Jr.
Janet L Rideout
Karla M Jacobus
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of BR9714312A publication Critical patent/BR9714312A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"MéTODO DE TRATAMENTO DE BRONQUITE COM TRIFOSFATO DE URIDINA E COMPOSTOS RELACIONADOS". é descrito um método de promover depuração de secreções mucosas retidas nos brónquios, bronquíolos e vias aéreas terminais inferiores de um sujeito em necessidade do referido tratamento. O método compreende administrar aos brónquios do sujeito fosfato de uridina tal como 5'trifosfato de uridina (UTP), ou tetrafosfato de di(uridina-5I)P1, P~ 4~ (U2P~ 4~), um análogo da UTP, ou qualquer outro análogo, em um teor efetivo para promover a depuração mucociliar e/ou tosse depurativa de fluido retido nos brónquios, bronquíolos e vias aéreas terminais inferiores. Os métodos de administração dos mesmos incluem, inalação de aerosol, qualquer suspensão líquida (incluindo gotas nasais ou pulverizações), forma oral (líquido ou pílula), injetáveis, instilação intra-operativa ou na forma de supositório.
BR9714312-0A 1996-11-07 1997-10-21 Método de tratamento de bronquite com trifosfato de uridina e composto relacionados BR9714312A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/744,367 US6159952A (en) 1996-11-07 1996-11-07 Method of treating bronchitis with uridine triphosphate and related compounds
PCT/US1997/018766 WO1998019685A1 (en) 1996-11-07 1997-10-21 Method of treating bronchitis with uridine triphosphates and related compounds

Publications (1)

Publication Number Publication Date
BR9714312A true BR9714312A (pt) 2000-05-02

Family

ID=24992452

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9714312-0A BR9714312A (pt) 1996-11-07 1997-10-21 Método de tratamento de bronquite com trifosfato de uridina e composto relacionados

Country Status (14)

Country Link
US (1) US6159952A (pt)
EP (1) EP0941099B1 (pt)
JP (1) JP2001505553A (pt)
KR (1) KR100518066B1 (pt)
CN (1) CN1115152C (pt)
AT (1) ATE249833T1 (pt)
AU (1) AU744981B2 (pt)
BR (1) BR9714312A (pt)
CA (1) CA2271126C (pt)
DE (1) DE69724991T2 (pt)
ES (1) ES2207723T3 (pt)
NO (1) NO992197L (pt)
NZ (1) NZ335540A (pt)
WO (1) WO1998019685A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
ATE261982T1 (de) 1997-07-25 2004-04-15 Inspire Pharmaceuticals Inc Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
TW593331B (en) * 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
US6251693B1 (en) 1998-07-30 2001-06-26 Micron Technology, Inc. Semiconductor processing methods and semiconductor defect detection methods
US6331529B1 (en) * 1999-02-26 2001-12-18 Inspire Pharmaceuticals, Inc. Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6555675B2 (en) 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
AR034635A1 (es) 2001-06-25 2004-03-03 Inspire Pharmaceuticals Inc Lubricacion de las articulaciones con agonistas del receptor purinergico p2y
MXPA04004215A (es) * 2001-11-06 2004-07-08 Inspire Pharmaceuticals Inc Metodo para el tratamiento o la prevencion de enfermedades inflamatorias.
CN1700894A (zh) * 2002-10-18 2005-11-23 莫利化学医药公司 使用羊毛硫抗生素治疗干眼病的方法
US7326683B2 (en) * 2004-05-06 2008-02-05 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
CA2565545A1 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US7851456B2 (en) * 2005-06-29 2010-12-14 Inspire Pharmaceuticals, Inc. P2Y6 receptor agonists for treating lung diseases
US20070249556A1 (en) * 2006-04-21 2007-10-25 Brubaker Kurt E Method of treating inflammation
JP2011026204A (ja) * 2007-11-26 2011-02-10 Rei Furukawa タバコの煙を吸入することにより引き起こされる疾患の予防及び／又は治療用組成物
WO2019112383A1 (ko) * 2017-12-08 2019-06-13 윤주석 금속 미네랄 디아미네이트 및 이의 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2122529A1 (de) * 1971-05-06 1972-12-14 Max Planck Gesellschaft zur Förde rung der Wissenschaften e V , 3400 Gottin gen Thiophosphatanaloge der Nucleosid di und tnphosphate sowie Verfahren zu ihrer Herstellung
US3960840A (en) * 1972-12-29 1976-06-01 University Of Illinois Foundaton Fluorescent derivatives of adenine-containing compounds
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
EP0508687B1 (en) * 1991-04-06 1995-09-13 Astra Pharmaceuticals Limited ATP analogues
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
FR2684299B1 (fr) * 1991-12-02 1995-03-24 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique et de l'amiloride.
FR2677250B1 (fr) * 1991-06-05 1995-01-20 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique.
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease

Also Published As

Publication number Publication date
ATE249833T1 (de) 2003-10-15
KR100518066B1 (ko) 2005-09-28
NO992197L (no) 1999-07-05
AU744981B2 (en) 2002-03-07
US6159952A (en) 2000-12-12
DE69724991T2 (de) 2004-11-11
NZ335540A (en) 2001-05-25
NO992197D0 (no) 1999-05-05
AU4986697A (en) 1998-05-29
WO1998019685A1 (en) 1998-05-14
CA2271126A1 (en) 1998-05-14
KR20000053094A (ko) 2000-08-25
EP0941099B1 (en) 2003-09-17
CN1236318A (zh) 1999-11-24
EP0941099A1 (en) 1999-09-15
CN1115152C (zh) 2003-07-23
DE69724991D1 (de) 2003-10-23
JP2001505553A (ja) 2001-04-24
ES2207723T3 (es) 2004-06-01
CA2271126C (en) 2008-04-08

Similar Documents

Publication Publication Date Title
BR9714312A (pt) Método de tratamento de bronquite com trifosfato de uridina e composto relacionados
US5763447C1 (en) Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
WO1997035591B1 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
DK0734249T3 (da) Hidtil ukendt og forbedret aminoglycosidformulering til aerosolisering
DE69716255D1 (de) Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln
DE69625906D1 (de) Dinukleotide zur verwendung in der behandlung von lungenkrankheiten
NZ313864A (en) Method of obtaining a mucous sample from the lung using triphosphate compounds
YU39695A (sh) Formulacija analoga insulina
DE69431290D1 (de) PULMONÄRE VERABREICHUNG DES LÖSLICHEN KOMPLEMENT-RECEPTORS TYP 1 sCR1
DE3650358D1 (de) Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis.
SE9502474L (sv) Farmaceutiska kompositioner för förhindrande och behandling av cancerösa sjukdomar samt process för beredning av dessa
IL142983A0 (en) Nucleosides with anti-hepatisis b virus activity
ATE321561T1 (de) Azidoderivate von beta-l-2'-nukleosiden zur hiv- infektionsbehandlung
HUP9802142A2 (hu) Na+/H+ -ioncsere inhibítorok alkalmazása a központi idegrendszer betegségeinek kezelésére és megelőzésére alkalmas gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1767 DE 20041116 POR TER SIDO APRESENTADA PAPELETA DE ESCLARECIMENTO.

B25A Requested transfer of rights approved

Owner name: INSPIRE PHARMACEUTICALS, INC. (US) , UNIVERSITY OF

Free format text: TRANSFERIDO 50% DE: INSPIRE PHARMACEUTICALS, INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERACAO(INT.CI.8) A61K 9/08, A61K 9/10, A61K 9/12, A61K 31/7068, A61K 31/7072, A61K 31/7076, A61K 31/7084; A61P 11/00, A61P 11/10, A61P 11/12;

Ipc: A61K 9/08, A61K 9/10, A61K 9/12, A61K 31/7068, A61

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE ESTE NAO ATENDE AO REQUISITO DE NOVIDADE ( ARTIGO. 8O COMBINADO COM ARTIGO. 11 DA LEI 92.79 DE 1996.